I have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I w ...

CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release. Precision Drilling Corporation (Precision or the Company) announced today that the Toronto Stock Exchange (the T ...

Core Insights - PDS Biotechnology Corporation is set to present updated data from the VERSATILE-002 trial, which evaluates the first-line treatment of Versamune® HPV in combination with KEYTRUDA® for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma at the ESMO Congress 2024 [1][2] Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers, as well as developing vaccines for infectious diseases [3] - The company plans to initiate a pivotal clinical trial in 2024 to advance its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [3] - Versamune® HPV, the company's lead investigational targeted immunotherapy, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate [3]

PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York Cit ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being unde ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher." Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ...

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the In ...

Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that it has received the official minutes from its meeting with the U.S. Food and Drug Administratio ...

Core Viewpoint - PDS Biotechnology Corporation is set to provide a clinical program update on August 1, 2024, focusing on its immunotherapy developments and upcoming pivotal clinical trials [1][2]. Company Overview - PDS Biotechnology is a late-stage immunotherapy company dedicated to enhancing the immune system's ability to target and eliminate cancers, as well as developing vaccines for infectious diseases [2]. - The company plans to initiate a pivotal clinical trial in 2024 for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [2]. Clinical Development - The lead investigational targeted immunotherapy, Versamune® HPV, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), along with a standard immune checkpoint inhibitor [2].

Core Insights - Precision Drilling reported quarterly earnings of $1.05 per share, exceeding the Zacks Consensus Estimate of a loss of $0.62 per share, but down from $1.21 per share a year ago [4] - The company achieved revenues of $313.71 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.53%, although this represents a decline from $316.89 million year-over-year [2] - Precision Drilling's stock has increased approximately 31.1% since the beginning of the year, outperforming the S&P 500's gain of 14.5% [3] Earnings Performance - The earnings surprise for the latest quarter was 269.35%, following a previous quarter where earnings were $1.88 per share against an expectation of $2 per share, resulting in a surprise of -6% [1] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [5] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.36 on revenues of $358.99 million, and for the current fiscal year, it is $6.03 on revenues of $1.47 billion [10] - The estimate revisions trend for Precision Drilling is currently unfavorable, leading to a Zacks Rank 5 (Strong Sell) for the stock, indicating expected underperformance in the near future [9] - The Oil and Gas - Drilling industry is ranked in the bottom 18% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [11]